Novo Nordisk swallows Dicerna and its RNAi pipeline in $3.3B buyout

John Carroll

Editor & Founder

Early this year researchers at Novo Nordisk were beaming as they announced the first drug identified in their RNAi alliance with Dicerna was headed into …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Novo Nordisk swallows Dicerna and its RNAi pipeline in $3.3B buyout

John Carroll

Editor & Founder

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Pfizer’s prostate cancer data leak shows promising results in early-stage study

Novartis returns for its anticoagulant in up to $3.1B buy of Blackstone’s Anthos

Judge halts some NIH cuts after 22 states sue

Vertex operations chief Stuart Arbuckle to retire

Merck KGaA confirms interest in acquiring cancer biotech SpringWorks

Reducing risk in drug development: The importance of validated MRD testing in lymphoid cancers

No­vo Nordisk swal­lows Dicer­na and its RNAi pipeline in $3.3B buy­out

Editor & Founder

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Novo Nordisk swallows Dicerna and its RNAi pipeline in $3.3B buyout